
Professor Lesley Jones
Professor, Division of Psychological Medicine and Clinical Neurosciences
- jonesl1@cardiff.ac.uk
- +44 (0)29 2068 8469
- 3.08, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ
- Available for postgraduate supervision
Overview
My laboratory has been working on Huntington's disease (HD) using genetics, bioinformatics, cell and animal models. HD is an inherited disease caused by an expanded repeated section of DNA and the length of the repeat partly determines age-at-onset of disease. I am particularly interested in genetic modifiers of HD. Genetic variation that modifies disease can be regarded as a therapeutic target since it modifies the disease in people. We showed that DNA repair mechanisms and the exact CAG repeat sequence alter HD age-at-onset and are investigating how this might cause HD in our model systems in the laboratory.
Genetic profiling: the key to Huntington’s treatment?
An interview at the Alzheimer's Research UK Conference 2019.
Biography
Current post (2012 - )
Professor of Neuropsychiatric genetics, Div Psychological Medicine Clinical Neuroscience and MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University. HEFCW funded. Reader (2007), Senior Lecturer (1999).
Education:
BSc (hons) Biochemistry 1st class (1985): PhD (1990). Cardiff University. I am not clinically qualified.
Honours and awards
Selected recent invited presentations
-
- June 2019: co-chair and session lead, Gordon Research Conference CAG Trinucleotide repeats;
- March 2019: Invited speaker Alzheimer’s Research UK, Harrogate, UK;
- Nov 2018: invited speaker, GlasgowNeuro conference, Royal Coll. Surgeons, Glasgow;
- April 2018: invited speaker, Genomics of Brain Disorders meeting, Wellcome Trust Sanger Centre;
- Oct 2017: invited speaker NINDS “Biomarkers in HD”, NIH, Washington, USA;
- June 2017: invited speaker, CAG Triplet Repeats Gordon Conference, Mount Snow, Vermont, USA;
Professional memberships
Collaborations
I collaborate closely with many of my colleagues locally in the MRC Centre for Neuropsychiatric Genetics and Genomics, the Institute for Neuroscience and Mental Health and the wider College of Biomedical and Life Sciences. In particular I collaborate with Peter Holmans, Vincent Dion, Nigel Williams, Valentina Escott-Price, Georgina Menzies, Gaynor Smith, Julie Williams, Rebecca Sims, John Atack and Simon Ward.
Externally I collaborate with:
- Sarah Tabrizi, University College London
- Gill Bates, University College London
- Stephen Jackson, University of Cambridge
- Jim Gusella, Marcy MacDonald and Jong-Min Lee, Massachusetts General Hospital, Harvard University
- Henry Houlden, University College London
- The International Genomics of Alzheimer’s disease Project
- Darren Monckton, University of Glasgow
- Lorena Beese, Duke University School of Medicine
- Ray Truant, McMaster University
- Bob Lahue, National University of Ireland
PhD students
- Branduff McAllister “Identification and characterisation of genetic variation that modifies age at onset in Huntington’s disease” (main supervisor with Thomas Massey, Peter Holmans and Nigel Williams): 2016
- Jasmine Donaldson, Wellcome Trust Integrated Neuroscience, “Characterising the DNA damage response in cellular models of Huntington’s disease” (main supervisor with Tom Massey and Nick Allen): 2016
- Anthony Warland, MRC funded "Characterising the dynamics of repeat expansion in Huntington’s disease" (main supervisor with Tom Massey and Nigel Williams): 2018
- Freja Sadler, UKDRI funded "Characterising the pathways to abnormal protein aggregation in dementia in Drosophila and induced pluripotent stem cell models" (main supervisor with Gaynor Smith, Tom Massey and Emyr Lloyd-Evans): 2018
- Laura Heraty, UKDI co-supervisor with Vincent Dion, 2019
- External co-supervisor for Davina Hensman-Moss (UCL) and Michael Flower (UCL)
Current Funding
- LoQus23 Therapeutics. MSH3: a disease modifying approach to Huntington’s disease. Jones (PI), Massey, Ward, Atack. 2019 – 2020 (18m), £535,349.
- CHDI. Integrating genetic and functional data to identify pathogenic pathways modifying the progression and phenotypic expression of Huntington's disease. Holmans (PI), Jones. May 2019 – April 2021 (24m): £353,485.
- CHDI. Pilot investigation to characterise the in vitro and in vivo effects of FAN1 in Huntington’s disease. Jones (PI), Massey, Allen. 2018 – 2020 (24m), £468,543.
- MRC PhD studentship “Characterising the dynamics of repeat expansion in Huntington’s disease” Jones (PI), Williams N, Massey T. (Oct 2018 – Sept 2021) £85,000;
- UKDRI PhD studentship “Biological dissection of phenotypic heterogeneity in HD” Jones (PI), Smith G, Massey T, Lloyd-Evans E. (Oct 2018 – Mar 2022) £100,000;
- ARUK “ARUK-PPG2018A-015 “Detecting simple repeat sequences in the genome and their effects in dementias.” £48,507 Jones L (PI), Holmans P, Sims R, Williams N. (2018 –2019);
- Wellcome Trust PhD studentship “DNA repair in Huntington’s disease and other repeat-associated disorders.” 109088/Z/15/A 2016 – 2019. £150,321;
- MRC Fellowship Dr Thomas Massey “Understanding the role of DNA repair in Huntington’s disease pathogenesis: towards novel therapeutic targets” £304,780 Aug 2016 – July 2019
- Association ofBritishNeurologists Dr Thomas Massey “The role of DNA repair inHuntington's Diseasepathogenesis.”Aug 2016 – Aug 2019 £30,000
- School of Medicine PhD award “Identification and characterisation of genetic variation that modifies age at onset in Huntington’s disease”. 2016 – 2019. £82,000
- MRC Momentum award, May 2017 – Apr 2020. Dementia Research Centre: £962,670K (Thomas (PI), Graham, Williams, Jones, Taylor, Morgan);
- MRC Centre “The Centre for Neuropsychiatric Genetics and Genomics” Co-applicant (the MRC Centre for Neuropsychiatric Genetics and Genomics) MR/L010305/1, 2014-2019, £1.7M;
Speaking engagements
2020
- May 2020: invited speaker, Huntington's disease Youth Association meeting, Glasgow, UK
2019
- Nov 2019: invited speaker, Bristol Neuro conference, Bristol;
- Nov 2019: invited seminar, National University of Ireland, Galway 2019:
- April 2019: invited speaker Alzheimer’s Research UK annual conference, Harrogate, UK
2018
- Nov 2018: invited seminar, Glasgow Neuro Society, Glasgow;
- Oct 2018: invited seminar, Universite de Lausanne, Center for Integrative Genomics;
- Sept 2018: invited speaker, EHDN Plenary meeting, Vienna;
- May 2018: invited speaker, Enroll-HD Congress, Quebec, Canada;
- May 2018: invited participant/presenter “Tackling gaps in developing life-changing treatments for dementia”, ARUK, London;
- April 2018: invited speaker, The 9th Intl Conf on Unstable Microsatellites & Human Disease, Italy;
- April 2018: invited speaker, Genomics of Brain Disorders meeting, Wellcome Trust Sanger Centre;
2017
- Dec 2017: invited speaker NECTAR meeting, Dublin, Dec 2017;
- Oct 2017: invited speaker NINDS “Biomarkers in HD”, NIH, Washington, USA;
- June 2017: invited speaker, CAG Triplet Repeats Gordon Conference, Mount Snow, Vermont, USA;
Committees and reviewing
External roles and responsibilities
- Chair of internal Wellcome Trust ISSF panel
- Member, Programme committee, Alzheimer’s Research UK conference 2020.
- Member, Executive Committee of the European Huntington’s Disease Network (EHDN), 2014 – 2022.
- Programme chair, EHDN Plenary meeting Vienna, Sept 2018.
- Chair Gordon conference “CAG trinucleotide repeats” June 2021 (vice-chair 2019).
- Member Alzheimer’s Research UK Scientific Advisory Board (2013 - ).
- Member Huntington Society of Canada Research Board (2016 - )
- Member FRIMEDBIO Panel 7 (Neuroscience) Research Council of Norway (2017 - ).
I regularly review for grant boards and journals nationally and internationally.
Publications
2022
- Rosser, A. E. and Jones, L. 2022. Huntington's disease gene hunters: an expanding tale. Movement Disorders Clinical Practice 9(3), pp. 330-333. (10.1002/mdc3.13375)
- McAllister, B. et al. 2022. Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience 25, pp. 446-457. (10.1038/s41593-022-01033-5)
- Bellenguez, C. et al. 2022. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics 54(4), pp. 412-436. (10.1038/s41588-022-01024-z)
- Lee, J. et al. 2022. Genetic modifiers of Huntington's disease differentially influence motor and cognitive domains.. [Online]. MedRxiv. (10.1101/2022.01.03.22268687) Available at: https://doi.org/10.1101/2022.01.03.22268687
2021
- McAllister, B. et al. 2021. Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurology 96(19), pp. e2395-e2406. (10.1212/WNL.0000000000011893)
- Hong, E. P. et al. 2021. Huntington's disease pathogenesis: two sequential components. Journal of Huntington's Disease 10(1), pp. 35-51. (10.3233/JHD-200427)
- Jones, L., Wheeler, V. C. and Pearson, C. E. 2021. Special issue: DNA repair and somatic repeat expansion in Huntington's disease. Journal of Huntington's Disease 10(1), pp. 3-5. (10.3233/JHD-219001)
- Donaldson, J., Powell, S., Rickards, N., Holmans, P. and Jones, L. 2021. What is the pathogenic CAG expansion length in Huntington’s disease?. Journal of Huntington's Disease 10(1), pp. 175-202. (10.3233/JHD-200445)
- Hong, E. P. et al. 2021. Association analysis of chromosome X to identify genetic modifiers of Huntington's disease. Journal of Huntington's Disease 10(3), pp. 367-375. (10.3233/JHD-210485)
2020
- Kim, K. et al. 2020. Genetic and functional analyses point to FAN1 as the source of multiple Huntington Disease modifier effects. American Journal of Human Genetics 107(1), pp. 96-110. (10.1016/j.ajhg.2020.05.012)
- Ellis, N. et al. 2020. Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s Disease. Biological Psychiatry 87(9), pp. 857-865. (10.1016/j.biopsych.2019.12.010)
- Flower, M., Lomeikaite, V., Holmans, P., Jones, L., Tabrizi, S. J. and Monckton, D. G. 2020. Reply: The repeat variant in MSH3 is not a genetic modifier for spinocerebellar ataxia type 3 and Friedreich’s ataxia. Brain 143(4), article number: e26. (10.1093/brain/awaa044)
- McAllister, B. et al. 2020. The onset and prevalence of motor and psychiatric symptoms in Huntington’s disease. [Online]. bioRxiv. (10.1101/2020.05.26.116798)
2019
- Ciosi, M. et al. 2019. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine 48, pp. 568-580. (10.1016/j.ebiom.2019.09.020)
- Lee, J. et al. 2019. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell 178(4), pp. 887-099.e14. (10.1016/j.cell.2019.06.036)
- Baker, E. et al. 2019. Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer’s disease. PLoS ONE 14(7), article number: e0218111. (10.1371/journal.pone.0218111)
- Flower, M. et al. 2019. MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1. Brain 142(7), pp. 1876-1886. (10.1093/brain/awz115)
- Kunkle, B. W. et al. 2019. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics 51(3), pp. 414-430. (10.1038/s41588-019-0358-2)
- Goold, R. et al. 2019. FAN1 modifies Huntington's disease progression by stabilising the expanded HTT CAG repeat. Human Molecular Genetics 28(4), pp. 650-661., article number: ddy375. (10.1093/hmg/ddy375)
- Benn, C. et al. 2019. Tackling gaps in developing life-changing treatments for dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5, pp. 241-253. (10.1016/j.trci.2019.05.001)
2018
- McNulty, P. et al. 2018. Reduced cancer incidence in Huntington's disease: analysis in the Registry study. Journal of Huntington's Disease 7(3), pp. 209-222. (10.3233/JHD-170263)
- Carboni, L. et al. 2018. Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression. Neuropsychopharmacology 43, pp. 2134-2145. (10.1038/s41386-018-0117-6)
- Massey, T., McAllister, B. and Jones, L. 2018. Methods for assessing DNA repair and repeat expansion in Huntington's Disease. In: Precious, S. V., Rosser, A. E. and Dunnett, S. B. eds. Huntington’s Disease., Vol. 1780. Methods in Molecular Biology Humana Press, pp. 483-495., (10.1007/978-1-4939-7825-0_22)
- Chao, M. J. et al. 2018. Population-specific genetic modification of Huntington's disease in Venezuela. PLoS Genetics 14(5), article number: e1007274. (10.1371/journal.pgen.1007274)
- Massey, T. and Jones, L. 2018. The central role of DNA damage and repair in CAG repeat diseases. Disease Models & Mechanisms 11(1), article number: dmm031930. (10.1242/dmm.031930)
2017
- Holmans, P. A., Massey, T. H. and Jones, L. 2017. Genetic modifiers of Mendelian disease: Huntington's disease and the trinucleotide repeat disorders. Human Molecular Genetics 26(R2), pp. R83-R90. (10.1093/hmg/ddx261)
- Lee, J. et al. 2017. A modifier of Huntington's disease onset at the MLH1 locus. Human Molecular Genetics 26(19), pp. 3859-3867. (10.1093/hmg/ddx286)
- Sims, R. et al. 2017. Rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics 49, pp. 1373-1384. (10.1038/ng.3916)
- Chao, M. J. et al. 2017. Haplotype-based stratification of Huntington's disease. European Journal of Human Genetics 25, pp. 1202-1209. (10.1038/ejhg.2017.125)
- Escott-Price, V. and Jones, L. 2017. Genomic profiling and diagnostic biomarkers in Alzheimer's disease. The Lancet Neurology 16(8), pp. 582-583. (10.1016/S1474-4422(17)30202-8)
- Hensman Moss, D. J. et al. 2017. Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease. Scientific Reports 7, pp. -., article number: 44849. (10.1038/srep44849)
- Bowles, K. R., Stone, T. C., Holmans, P. A., Allen, N. D., Dunnett, S. B. and Jones, L. 2017. SMAD transcription factors are altered in cell models of HD and regulate HTT expression. Cellular Signalling 31, pp. 1-14. (10.1016/j.cellsig.2016.12.005)
- Morgan, A. et al. 2017. The correlation between inflammatory biomarkers and polygenic risk score in Alzheimer's Disease. Journal of Alzheimer's Disease 56(1), pp. 25-36. (10.3233/JAD-160889)
- Jones, L., Houlden, H. and Tabrizi, S. J. 2017. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology 16(1), pp. 88-96. (10.1016/S1474-4422(16)30350-7)
2016
- Bowles, K. R., Brooks, S. P., Hughes, A., Dunnett, S. B. and Jones, L. 2016. Correction: Huntingtin Subcellular localisation is regulated by kinase signalling activity in the StHdhQ111 model of HD. PLoS ONE 11(10), article number: e0165069. (10.1371/journal.pone.0165069)
- Precious, S. V. et al. 2016. FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation. Experimental Neurology 282, pp. 9-18. (10.1016/j.expneurol.2016.05.002)
- Thomas, R. S., Henson, A., Gerrish, A., Jones, L., Williams, J. and Kidd, E. J. 2016. Decreasing the expression of PICALM reduces endocytosis and the activity of β-secretase: implications for Alzheimer's disease. BMC Neuroscience 17, article number: 50. (10.1186/s12868-016-0288-1)
- Miller, J. R. C. et al. 2016. RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Human Molecular Genetics 25(14), pp. 2893-2904. (10.1093/hmg/ddw142)
- Bettencourt, C. et al. 2016. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Annals of Neurology 79(6), pp. 983-990. (10.1002/ana.24656)
- Bayram-Weston, Z., Jones, L., Dunnett, S. B. and Brooks, S. P. 2016. Comparison of mHTT antibodies in Huntington's disease mouse models reveal specific binding profiles and steady-state ubiquitin levels with disease development.. PloS One (10.1371/journal.pone.0155834)
- Keum, J. W. et al. 2016. The HTT CAG expansion mutation determines age at death but not disease duration in Huntington’s Disease. American Journal of Human Genetics 98(2), pp. 287-298. (10.1016/j.ajhg.2015.12.018)
- Keum, J. et al. 2016. The HTT CAG-Expansion mutation determines age at death but not disease duration in Huntington disease. American Journal of Human Genetics 98(2), pp. 287-298. (10.1016/j.ajhg.2015.12.018)
- Jun, G. et al. 2016. A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry 21, pp. 108-117. (10.1038/mp.2015.23)
2015
- Escott-Price, V. et al. 2015. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain 138(12), pp. 3673-3684. (10.1093/brain/awv268)
- Bayram-Weston, Z. et al. 2015. Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington's disease are not reflected in mutant Huntingtin inclusion prevalence. BMC Genomics 16, pp. -., article number: 1079. (10.1186/s12864-015-2251-4)
- Bowles, K. R., Brooks, S. P., Dunnett, S. B. and Jones, L. 2015. Huntingtin subcellular localisation is regulated by Kinase signalling activity in the StHdhQ111 model of HD. PLoS ONE 10(12), article number: e0144864. (10.1371/journal.pone.0144864)
- Lee, J. M. et al. 2015. Identification of genetic factors that modify clinical onset of Huntington's disease. Cell 162(3), pp. 516-526. (10.1016/j.cell.2015.07.003)
- Mort, M. E., Carlisle, F., Waite, A., Elliston, L., Allen, N. D., Jones, L. and Hughes, A. 2015. Huntingtin exists as multiple splice forms in human brain. Journal of Huntington's Disease 4(2), pp. 161-171. (10.3233/JHD-150151)
- Jones, L. et al. 2015. Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia 11(6), pp. 658-671. (10.1016/j.jalz.2014.05.1757)
- Correia, K. et al. 2015. The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. Journal of Huntington's Disease 4(3), pp. 279-284. (10.3233/JHD-150169)
2014
- Hughes, A., Mort, M., Carlisle, F. and Jones, L. 2014. B04 Alternative Splicing In Htt [Conference abstract]. Journal of Neurology, Neurosurgery & Psychiatry 85(Suppl), pp. A10. (10.1136/jnnp-2014-309032.32)
- Escott-Price, V. et al. 2014. Gene-wide analysis detects two new susceptibility genes for Alzheimer's Disease. PLoS ONE 9(6), article number: e94661. (10.1371/journal.pone.0094661)
- Hughes, A., Mort, M. E., Elliston, L. A., Thomas, R. M., Brooks, S. P., Dunnett, S. B. and Jones, L. 2014. Identification of novel alternative splicing events in the Huntingtin gene and assessment of the functional consequences using structural protein homology modelling. Journal of Molecular Biology 426(7), pp. 1428-1438. (10.1016/j.jmb.2013.12.028)
- Bowles, K. and Jones, L. 2014. Kinase signalling in Huntington's disease. Journal of Huntington's Disease 3, pp. 89-123. (10.3233/JHD-140106)
- Hughes, A. and Jones, L. 2014. Pathogenic mechanisms in Huntington's disease. In: Bates, G., Tabrizi, S. and Jones, L. eds. Huntington's Disease, 4th Edition. Oxford University Press
2013
- Lambert, J. et al. 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease [Letter]. Nature Genetics 45(12), pp. 1452-1458. (10.1038/ng.2802)
- Holmans, P. A. et al. 2013. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics 22(5), pp. 1039-1049. (10.1093/hmg/dds492)
- Taylor, D. M. et al. 2013. MAP Kinase Phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's Disease via additive effects of JNK and p38 inhibition. Journal of Neuroscience 33(6), pp. 2313-2325. (10.1523/JNEUROSCI.4965-11.2013)
2012
- Hollingworth, P. et al. 2012. Genome-wide association study of Alzheimer's disease with psychotic symptoms. Molecular Psychiatry 17(12), pp. 1316-1327. (10.1038/mp.2011.125)
- Deschepper, M. P., Hoogendoorn, B., Brooks, S. P., Dunnett, S. B. and Jones, L. 2012. Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes. Brain Research Bulletin 88(2-3), pp. 210-222. (10.1016/j.brainresbull.2011.01.012)
- Brooks, S. P., Higgs, G., Jones, L. and Dunnett, S. B. 2012. Longitudinal analysis of the behavioural phenotype in HdhQ92 Huntington's disease knock-in mice. Brain Research Bulletin 88(2-3), pp. 148-155. (10.1016/j.brainresbull.2010.05.003)
- Brooks, S. P., Higgs, G., Jones, L. and Dunnett, S. B. 2012. Longitudinal analysis of the behavioural phenotype in Hdh(CAG)150 Huntington's disease knock-in mice. Brain Research Bulletin 88(2-3), pp. 182-188. (10.1016/j.brainresbull.2010.05.004)
- Bayram-Weston, Z., Torres, E. M., Jones, L., Dunnett, S. B. and Brooks, S. P. 2012. Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh((CAG)150) Huntington's disease knock-in mouse. Brain Research Bulletin 88(2-3), pp. 189-198. (10.1016/j.brainresbull.2011.03.014)
- Brooks, S. P., Higgs, G., Janghra, N., Jones, L. and Dunnett, S. B. 2012. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice. Brain Research Bulletin 88(2-3), pp. 113-120. (10.1016/j.brainresbull.2010.05.005)
- Brooks, S. P., Janghra, N., Workman, V. L., Bayram-Weston, Z., Jones, L. and Dunnett, S. B. 2012. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Research Bulletin 88(2-3), pp. 94-103. (10.1016/j.brainresbull.2011.01.010)
- Trueman, R. C., Dunnett, S. B., Jones, L. and Brooks, S. P. 2012. Five choice serial reaction time performance in the HdhQ92 mouse model of Huntington's disease. Brain Research Bulletin 88(2-3), pp. 163-170. (10.1016/j.brainresbull.2011.10.019)
- Bayram-Weston, Z., Jones, L., Dunnett, S. B. and Brooks, S. P. 2012. Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice. Brain Research Bulletin 88(2-3), pp. 137-147. (10.1016/j.brainresbull.2011.05.005)
- Bayram-Weston, Z., Jones, L., Dunnett, S. B. and Brooks, S. P. 2012. Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice. Brain Research Bulletin 88(2-3), pp. 104-112. (10.1016/j.brainresbull.2011.07.009)
- Trueman, R. C., Jones, L., Dunnett, S. B. and Brooks, S. P. 2012. Early onset deficits on the delayed alternation task in the HdhQ92 knock-in mouse model of Huntington's disease. Brain Research Bulletin 88(2-3), pp. 156-162. (10.1016/j.brainresbull.2011.03.012)
- Bayram-Weston, Z., Jones, L., Dunnett, S. B. and Brooks, S. P. 2012. Light and electron microscopic characterization of the evolution of cellular pathology in HdhQ92 Huntington's disease knock-in mice. Brain Research Bulletin 88(2-3), pp. 171-181. (10.1016/j.brainresbull.2011.03.013)
- Brooks, S. P., Janghra, N., Higgs, G. V., Bayram-Weston, Z., Heuer, A., Jones, L. and Dunnett, S. B. 2012. Selective cognitive impairment in the YAC128 Huntington's disease mouse. Brain Research Bulletin 88(2-3), pp. 121-129. (10.1016/j.brainresbull.2011.05.010)
- Brooks, S. P., Jones, L. and Dunnett, S. B. 2012. Longitudinal analyses of operant performance on the serial implicit learning task (SILT) in the YAC128 Huntington's disease mouse line. Brain Research Bulletin 88(2-3), pp. 130-136. (10.1016/j.brainresbull.2011.06.008)
- Bowles, K. R., Brooks, S. P., Dunnett, S. B. and Jones, L. 2012. Gene expression and behaviour in mouse models of HD. Brain Research Bulletin 88(2-3), pp. 276-284. (10.1016/j.brainresbull.2011.07.021)
- Fielding, S. A., Brooks, S. P., Klein, A., Bayram-Weston, Z., Jones, L. and Dunnett, S. B. 2012. Profiles of motor and cognitive impairment in the transgenic rat model of Huntington's disease. Brain Research Bulletin 88(2-3), pp. 223-236. (10.1016/j.brainresbull.2011.09.011)
- Brooks, S. P., Jones, L. and Dunnett, S. B. 2012. Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease. Brain Research Bulletin 88(2-3), pp. 81-93. (10.1016/j.brainresbull.2011.10.002)
- Giles, P. J., Elliston, L. A., Higgs, G., Brooks, S. P., Dunnett, S. B. and Jones, L. 2012. Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease. Brain Research Bulletin 88(2-3), pp. 199-209. (10.1016/j.brainresbull.2011.10.001)
- Richards, A. et al. 2012. Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain. Molecular Psychiatry 17(2), pp. 193-201. (10.1038/mp.2011.11)
- Gerrish, A. et al. 2012. The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's Disease. Journal of Alzheimer's Disease 28(2), pp. 377-387. (10.3233/JAD-2011-110824)
- Feyeux, M. et al. 2012. Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. Human Molecular Genetics 21(17), pp. 3883-3895. (10.1093/hmg/dds216)
- Hughes, A., Rosser, A. E. and Jones, L. 2012. E06 Family history curation in Huntington's disease: a survey of the data so far. Journal of Neurology, Neurosurgery & Psychiatry 83(Suppl), pp. A21-A21. (10.1136/jnnp-2012-303524.65)
- Bayram-Weston, Z., Jones, L., Dunnett, S. B. and Brooks, S. P. 2012. B08 Differential sensitivity of aggregate markers in HdhQ150 and YAC128 HD mouse models. Journal of Neurology, Neurosurgery & Psychiatry 83(Suppl), pp. A8-A8. (10.1136/jnnp-2012-303524.24)
2011
- Hollingworth, P. et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics 43(5), pp. 429-435. (10.1038/ng.803)
- Jones, L. and Hughes, A. 2011. Pathogenic mechanisms in Huntington's Disease. International Review of Neurobiology 98, pp. 373-418. (10.1016/B978-0-12-381328-2.00015-8)
- Sims, R. et al. 2011. No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156(7), pp. 764-771. (10.1002/ajmg.b.31216)
- Hughes, A. and Jones, L. 2011. Huntingtin localisation studies - a technical review. Plos Currents 3, pp. RRN1211. (10.1371/currents.RRN1211)
2010
- Craddock, N. J. et al. 2010. Strong genetic evidence for a selective influence of GABAA receptors on a component of the bipolar disorder phenotype [Corrigendum]. Molecular Psychiatry 15(11), pp. 1121-1121. (10.1038/mp.2010.62)
- Jones, L. et al. 2010. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 5(11), article number: e13950. (10.1371/journal.pone.0013950)
- Brooks, S. P., Jones, L. and Dunnett, S. B. 2010. Frontostriatal pathology in the (C57BL/6J) YAC128 mouse uncovered by the operant delayed alternation task [Meeting abstract]. Journal of Neurology, Neurosurgery and Psychiatry 81(1), pp. A9-A10. (10.1136/jnnp.2010.222570.29)
- Hughes, A., Ersoy, N., Elliston, L. A. and Jones, L. 2010. Protein localisation studies: Where is Huntingtin hiding? [Meeting abstract]. Journal of Neurology, Neurosurgery and Psychiatry 81(1), pp. A1. (10.1136/jnnp.2010.222570.3)
- Hollingworth, P., Harold, D., Jones, L., Owen, M. J. and Williams, J. 2010. Alzheimer's disease genetics: current knowledge and future challenges. International Journal of Geriatric Psychiatry 26(8), pp. 793-802. (10.1002/gps.2628)
- Jones, L., Harold, D. and Williams, J. 2010. Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1801(8), pp. 754-761. (10.1016/j.bbalip.2010.04.005)
2009
- Trueman, R. C., Brooks, S. P., Jones, L. and Dunnett, S. B. 2009. Rule learning, visuospatial function and motor performance in the Hdh(Q92) knock-in mouse model of Huntington's disease. Behavioural Brain Research 203(2), pp. 215-222. (10.1016/j.bbr.2009.05.006)
- Wood, I., Gray, N. and Jones, L. 2009. Gene expression in neuronal disease. Biochemical Society Transactions 37(6), pp. 1261-1262. (10.1042/BST0371261)
2008
- Packer, A. N., Xing, Y., Harper, S. Q., Jones, L. and Davidson, B. L. 2008. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. Journal of Neuroscience 28(53), pp. 14341-14346. (10.1523/JNEUROSCI.2390-08.2008)
- Hodges, A. K., Hughes, G., Brooks, S. P., Elliston, L. A., Holmans, P. A., Dunnett, S. B. and Jones, L. 2008. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes, Brain and Behavior 7(3), pp. 288-299. (10.1111/j.1601-183X.2007.00350.x)
- Trueman, R. C., Brooks, S. P., Jones, L. and Dunnett, S. B. 2008. Time course of choice reaction time deficits in the Hdh Q92/Q92 knock-in mouse model of Huntington's disease. Behavioural Brain Research 189(2), pp. 317-334. (10.1016/j.bbr.2008.01.020)
- Li, Y. et al. 2008. Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Human Molecular Genetics 17(5), pp. 759-767. (10.1093/hmg/ddm348)
- Bray, N. J. et al. 2008. Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1. Human Molecular Genetics 17(8), pp. 1169-1174. (10.1093/hmg/ddn006)
- Richards, A. L., Holmans, P. A., O'Donovan, M. C., Owen, M. J. and Jones, L. 2008. A comparison of four clustering methods for brain expression microarray data. BMC Bioinformatics 9, article number: 490. (10.1186/1471-2105-9-490)
2007
- Strand, A. D. et al. 2007. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. Journal of Neuroscience 27(43), pp. 11758-11768. (10.1523/JNEUROSCI.2461-07.2007)
- Morgan, A. et al. 2007. Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B(6), pp. 762-770. (10.1002/ajmg.b.30509)
- Harold, D. et al. 2007. Interaction between theADAM12 andSH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B(4), pp. 448-452. (10.1002/ajmg.b.30456)
- Kuhn, A. et al. 2007. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics 16(15), pp. 1845-1861. (10.1093/hmg/ddm133)
- Strand, A. D. et al. 2007. Conservation of regional gene expression in mouse and human brain. PLOS Genetics 3(4), article number: e59. (10.1371/journal.pgen.0030059)
- Trueman, R. C., Brooks, S. P., Jones, L. and Dunnett, S. B. 2007. The operant serial implicit learning task reveals early onset motor learning deficits in the HdhQ92 knock-in mouse model of Huntington's disease. European Journal of Neuroscience 25(2), pp. 551-558. (10.1111/j.1460-9568.2007.05307.x)
2006
- Bray, N. J. et al. 2006. Cis- and trans-acting loci influence expression of DTNBP1, a susceptibility gene for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 141B(7), pp. 723-724.
- Georgieva, L. et al. 2006. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 103(33), pp. 12469-12474. (10.1073/pnas.0603029103)
- Brooks, S., Betteridge, H., Trueman, R., Jones, L. and Dunnett, S. 2006. Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease. Brain Research Bulletin 69(4), pp. 452-7. (10.1016/j.brainresbull.2006.02.011)
- Jones, L. et al. 2006. Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BioMed Central Bioinformatics 7(1), article number: 211. (10.1186/1471-2105-7-211)
- Hodges, A. K. et al. 2006. Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics 15(6), pp. 965-977. (10.1093/hmg/ddl013)
- Harold, D. et al. 2006. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease. Pharmacogenetics and genomics 16(2), pp. 75-77.
- Grupe, A. et al. 2006. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. The American Journal of Human Genetics 78(1), pp. 78-88.
2005
- Hodges, A. et al. 2005. Regional specificity of transcriptional changes in early grade Huntington's disease brain. Journal of Neurology, Neurosurgery and Psychiatry 76, pp. A16-A16.
- Jones, L., Elliston, L. A., Caswell, R. and Ersoy, N. 2005. Mutant huntingtin represses transcription from the thyroid hormone receptor. Journal of Neurology, Neurosurgery and Psychiatry 76, pp. A17-A17.
- Brooks, S. P., Higgs, G., Trueman, R. C., Dunnett, S. B., Cheng, P., Redfern, A. R. and Jones, L. 2005. Longitudinal behavioural characterisation of the Q92 mouse line. Journal of Neurology, Neurosurgery and Psychiatry 76, pp. A48-A48.
- Hughes, G. P. et al. 2005. Integrating behaviour and brain gene expression in Huntington's disease transgenic mouse models. Journal of Neurology, Neurosurgery and Psychiatry 76, pp. A41-A41.
- Redfern, A. et al. 2005. Global gene expression profiling in the hippocampus and frontal cortex of Escitalopram-treated Learned Helplessness rats. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 138B(1), pp. 107-107.
- Brooks, S. P., Pask, T., Jones, L. and Dunnett, S. B. 2005. Behavioural profiles of inbred mouse strains used as transgenic backgrounds. II: cognitive tests. Genes, Brain and Behavior 4(5), pp. 307-317. (10.1111/j.1601-183X.2004.00109.x)
- Holmans, P. A. et al. 2005. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 135B(1), pp. 24-32. (10.1002/ajmg.b.30114)
- Morton, A. J., Hunt, M. J., Hodges, A. K., Lewis, P. D., Redfern, A. J., Dunnett, S. B. and Jones, L. 2005. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. European Journal of Neuroscience 21(4), pp. 855-870. (10.1111/j.1460-9568.2005.03895.x)
2004
- Hughes, A., Errington, R. J., Fricker-Gates, R. and Jones, L. 2004. Endophilin A3 forms filamentous structures that colocalise with microtubules but not with actin filaments. Molecular Brain Research 128(2), pp. 182-192. (10.1016/j.molbrainres.2004.06.016)
- Brooks, S. P., Pask, T., Jones, L. and Dunnett, S. B. 2004. Behavioural profiles of inbred mouse strains used as transgenic backgrounds. I: motor tests. Genes, Brain and Behavior 3(4), pp. 206-215. (10.1111/j.1601-183X.2004.00072.x)
- Myers, A. J. et al. 2004. Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. American Journal of Medical Genetics 124B(1), pp. 29-37. (10.1002/ajmg.b.20036)
- Busby, V. et al. 2004. Alpha-T-Catenin Is Expressed in Human Brain and Interacts With the Wnt Signaling Pathway But Is Not Responsible for Linkage to Chromosome 10 in Alzheimer's Disease. Neuromolecular Medicine 5(2), pp. 133-146. (10.1385/NMM:5:2:133)
2003
- Harold, D. et al. 2003. Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Human Genetics 113(3), pp. 258-267. (10.1007/s00439-003-0960-2)
- Reid, S. J. et al. 2003. Molecular investigation of TBP allele length:. Neurobiology of Disease 13(1), pp. 37-45. (10.1016/S0969-9961(03)00014-7)
- von Horsten, S. et al. 2003. Transgenic rat model of Huntington's disease. Human Molecular Genetics 12(6), pp. 617-624. (10.1093/hmg/ddg075)
- Jones, L. et al. 2003. beta-Ketoacyl-acyl carrier protein synthase III from pea (Pisum sativum L.): properties, inhibition by a novel thiolactomycin analogue and isolation of a cDNA clone encoding the enzyme. Planta 216(5), pp. 752-761.
2002
- van Roon-Mom, W. M., Reid, S. J., Jones, L., MacDonald, M. E., Faull, R. L. and Snell, R. G. 2002. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Molecular Brain Research 109(1-2), pp. 1-10. (10.1016/S0169-328X(02)00450-3)
- Duce, J., Hartog, C., Elliston, L. A., Neal, J. W., Nicholson, L. F. B. and Jones, L. 2002. Transcriptional dysregulation in Huntington's disease. American Journal of Human Genetics 69(4), pp. 545-545. (10.1007/978-1-4615-0715-4_49)
- Myers, A. et al. 2002. Full genome screen for Alzheimer disease: Stage II analysis. American Journal Of Medical Genetics Part A 114(2), pp. 235-244. (10.1002/ajmg.10183)
- Jones, L. 2002. The cell biology of Huntington's disease. In: Bates, G., Harper, P. S. and Jones, A. L. eds. Huntington's Disease (3rd ed.). Oxford Monographs on Medical Genetics Vol. 45. Oxford: Oxford University Press, pp. 348-386.
2001
- Abraham, R. et al. 2001. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Human Genetics 109(6), pp. 646-652. (10.1007/s00439-001-0614-1)
- Harper, P., Evans, R., Elliston, L., Ironside, J. W., Jones, L. and Lazarou, L. 2001. Huntington's disease intermediate allele and new variant CJD. American Journal of Human Genetics 69(4), pp. 547-547.
- Reid, S. J. et al. 2001. Expression and population studies of the TATA-box binding protein polyglutamine region at normal and expanded lengths.. American Journal of Human Genetics 69(4), pp. 424-424.
- Jones, L., Duce, J., Elliston, L. and Harper, P. 2001. The involvement of transcriptional repressor proteins in Huntington's disease. Journal of Medical Genetics 38(Suppl1), pp. S65-S65.
2000
- Myers, A. et al. 2000. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290(5500), pp. 2304-2305. (10.1126/science.290.5500.2304)
- Jones, L., Herbert, D., Rutter, A. J., Dancer, J. E. and Harwood, J. L. 2000. Novel inhibitors of the condensing enzymes of the type II fatty acid synthase of pea (Pisum sativum).. Biochemical Journal 347(1), pp. 205-209. (10.1042/bj3470205)
1999
- Boutell, J. M., Thomas, P., Neal, J. W., Weston, V. J., Duce, J., Harper, P. S. and Jones, L. 1999. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Human Molecular Genetics 8(9), pp. 1647-1655. (10.1093/hmg/8.9.1647)
- Jones, L. 1999. The localization and interactions of huntingtin. Philosophical Transactions of the Royal Society of London Series B - Biological Sciences 354(1386), pp. 1021-1027. (10.1098/rstb.1999.0454)
- Wilkinson, F. L. et al. 1999. Localization of rabbit huntingtin using a new panel of monoclonal antibodies. Molecular Brain Research 69(1), pp. 10-20. (10.1016/S0169-328X(99)00097-2)
- Sieradzan, K. A., Mechan, A. O., Jones, L., Wanker, E. E., Nukina, N. and Mann, D. M. 1999. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Experimental Neurology 156(1), pp. 92-99. (10.1006/exnr.1998.7005)
- Kehoe, P., Krawczak, M., Harper, P. S., Owen, M. J. and Jones, L. 1999. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. Journal of Medical Genetics 36(2), pp. 108-111. (10.1136/jmg.36.2.108)
1998
- Thomas, P., Wilkinson, F., Nguyen, T. M., Harper, P. S., Neal, J. W., Morris, G. E. and Jones, L. 1998. Full length huntingtin is not detected in intranuclear inclusions in Huntington's disease brain. Biochemical Society Transactions 26(3), pp. S243. (10.1042/bst026s243)
- Singhrao, S. K., Thomas, P., Wood, D. J., MacMillan, J. C., Neal, J. W., Harper, P. S. and Jones, L. 1998. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington's, Alzheimer's, and Pick's diseases. Experimental Neurology 150(2), pp. 213-222. (10.1006/exnr.1998.6778)
- Boutell, J. M., Wood, J. D., Harper, P. S. and Jones, L. 1998. Huntingtin interacts with cystathionine beta-synthase. Human Molecular Genetics 7(3), pp. 371-378. (10.1093/hmg/7.3.371)
1997
- Jones, L. et al. 1997. No evidence for expanded polyglutamine sequences in bipolar disorder and schizophrenia. Molecular Psychiatry 2(6), pp. 478-482. (10.1038/sj.mp.4000297)
- Boutell, J. M., Krusche, L. A., Harper, P. S. and Jones, L. 1997. Generation of clones with varying trinucleotide repeat sires using intrinsic instability in E-coli. American Journal of Human Genetics 61(4), pp. A404-A404.
- Singhrao, S. K., Thomas, P., Wood, J. D., Harper, P. S., Neal, J. W. and Jones, L. 1997. Huntingtin is associated with intracellular neuropathology in Huntington's, Alzheimer's and Pick's disease. American Journal of Human Genetics 61(4), pp. A321-A321.
- Jones, L., Boutell, J. M., Wood, J. D. and Harper, P. S. 1997. Two proteins which interact with the N-terminus of huntingtin. American Journal of Human Genetics 61(4), pp. A311-A311.
- Jones, L., Wood, J. D. and Harper, P. S. 1997. Huntington disease: advances in molecular and cell biology. Journal of Inherited Metabolic Disease 20(2), pp. 125-138. (10.1023/A:1005340302695)
1996
- Wood, J. D., MacMillan, J. C., Harper, P. S., Lowenstein, P. R. and Jones, L. 1996. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. Human Molecular Genetics 5(4), pp. 481-487. (10.1093/hmg/5.4.481)
1995
- Wood, J., MacMillan, J. C., Thomas, P., Lowenstein, P. R., Harper, P. S. and Jones, L. 1995. Characterising the Huntington's disease gene product. Biochemical Society Transactions 23(4), pp. 595S. (10.1042/bst023595s)
- MacMillan, J. C., Thomas, P., Wood, J., Jones, L., Harper, P. S. and Lowenstein, P. R. 1995. Light microscopic analysis of the distribution of the Huntington disease protein in murine brain. American Journal of Human Genetics 57(4), pp. 1823-1823.
- Wood, J., MacMillan, J. C., Harper, P. S. and Jones, L. 1995. Subcellular-distribution and characterization of the Huntingtons-Disease gene-product in human and mouse brain.. American Journal of Human Genetics 57(4), pp. 1473-1473.
- Jones, L., Dancer, J. E. and Harwood, J. L. 1995. Effect of thiolactomycin on fatty acid synthesis in peas. Phytochemistry 39(3), pp. 511. (10.1016/0031-9422(95)00033-4)
1994
- Jones, L., Dancer, J. E. and Harwood, J. L. 1994. The effect of thiolactomycin analogues on fatty acid synthesis in peas (Pisum sativum cv. Onward).. Biochemical Society Transactions 22(3), pp. 258S. (10.1042/bst022258s)
1993
- Jones, L., Lloyd, D. and Harwood, J. L. 1993. Rapid induction of microsomal delta12(w 6)-desaturase activity in chilledAcanthamoeba castellanii. Biochemical Journal 296(1), pp. 183-188. (10.1042/bj2960183)
- Jones, L. and Harwood, J. L. 1993. Lipids and lipid metabolism in the marine alga Enteromorpha intestinalis. Phytochemistry 34(4), pp. 969-972. (10.1016/S0031-9422(00)90695-2)
- Jones, L. and Harwood, J. 1993. Lipid-metabolism in the brown marine-algae fucus-vesiculosus and ascophyllum-nodosum. Journal of Experimental Botany 44(264), pp. 1203-1210. (10.1093/jxb/44.7.1203)
- Jones, L., Kille, P., Dancer, J. E. and Harwood, J. L. 1993. The cloning and overexpression ofE coliacyl carrier protein (ACP). Biochemical Society Transactions 21(2), pp. 202S-202S. (10.1042/bst021202s)
- Jones, L., Kille, P., Dancer, J. E. and Harwood, J. L. 1993. The cloning and overexpression of escherichia-coli acyl carrier protein. Grasas Y Aceites 44(2), pp. 116-117.
- Jones, L., Hann, A. C., Harwood, J. L. and Lloyd, D. 1993. Temperature-induced membrane-lipid adaptation inAcanthamoeba castellanii. Biochemical Journal 290(1), pp. 273-278. (10.1042/bj2900273)
1992
- Jones, L. and Harwood, J. L. 1992. Lipid composition of the brown algae fucus vesiculosus and Ascophyllum nodosum. Phytochemistry 31(10), pp. 3397-3403. (10.1016/0031-9422(92)83693-S)
- Jones, L., Harwood, J. L. and Lloyd, D. 1992. Induction of delta12-desaturase activity during temperature adaptation in Acanthamoeba castellanii. Biochemical Society Transactions 20(2), pp. 170S-170S. (10.1042/bst020170s)
1991
- Jones, L., Pruitt, N. L., Lloyd, D. and Harwood, J. L. 1991. Temperature-induced Changes in the Synthesis of Unsaturated Fatty Acids byAcanthamoeba castellanii. The Journal of Protozoology 38(6), pp. 532-536. (10.1111/j.1550-7408.1991.tb06076.x)
- Jones, L., Lloyd, D., Hann, A. C. and Harwood, J. L. 1991. Lipid changes in individual membranes of Acanthamoeba castellanii during temperature adaptation. Biochemical Society Transactions 19(3), pp. 318S-318S. (10.1042/bst019318s)
1990
- Jones, L., Pruitt, N. L., Lloyd, D. and Harwood, J. L. 1990. Effect of growth temperature on fatty acid biosynthesis in Acanthamoeba castellanii. Biochemical Society Transactions 18(4), pp. 627. (10.1042/bst0180627)
1989
- Harwood, J. L. and Jones, L. 1989. Lipid Metabolism in Algae. Advances in Botanical Research 16, pp. 1-53. (10.1016/S0065-2296(08)60238-4)
- Pettitt, T., Jones, L. and Harwood, J. 1989. Lipids of the marine red algae, chondrus-crispus and polysiphonia-lanosa. Phytochemistry 28(2), pp. 399-405.
- Pettitt, T. R., Jones, L. and Harwood, J. L. 1989. Lipid metabolism in the red marine algae Chondrus crispus and Polysiphonia lanosa as modified by temperature. Phytochemistry 28(8), pp. 2053-2058. (10.1016/S0031-9422(00)97919-6)
1988
- Jones, L. and Harwood, J. 1988. Effects of heavy-metals on lipid-metabolism in marine-algae. Biochemical Society Transactions 16(3), pp. 275-276.
1987
- Jones, L. and Harwood, J. L. 1987. Comparative aspects of lipid metabolism in marine algae. Biochemical Society Transactions 15(3), pp. 482-482. (10.1042/bst0150482)
Genetic modifiers in Huntington’s disease
Our latest research just published in Cell (https://www.sciencedirect.com/science/article/pii/S0092867419307391) follows up our first analysis of genetic modifiers in HD from 2015 (GeM-HD http://dx.doi.org/10.1016/j.cell.2015.07.003). Our latest data indicate that not only are pathways involved in DNA handling and repair involved in altering the age at which people get Huntington's disease, but that the sequence of the disease-causing CAG repeat is critical too. Most people - whether or not they have HD - have two copies of a CAG repeat that has a CAACAG hexamer at the 3' end. In a few people though, the repeat has a different sequence at the 3' end: people with expanded CAG repeats with CAACAGCAACAG at the 3' end get Huntington's disease much later than expected, whereas people with no CAA repeat at all, just a pure CAG, get the disease much earlier than expected. This is because the repeat lengths are being measured incorrectly, and it is the pure CAG length rather than the translated HTT protein polyglutamine length that is important, but is also likely due to other factors, potentially related to the structures in the DNA adopted by the repeats of different sequences.
Our motivation in these studies was to identify variation that could delay or precipitate disease onset as the biological pathways that this variation lies in are ideal therapeutic targets, as we know they have this effect in people carrying the mutation. We are extending this study in collaboration with Jim Gusella, Marcy MacDonald, Vanessa Wheeler and Jong-Min Lee (MGH, Boston USA), Seung Kwak (CHDI, USA) and Michael Orth (Ulm University, Germany). I was also the Lead Facilitator of the Genetic Modifiers Working Group (GMWG) of the European Huntington’s Disease Network. I collaborate closely with SarahTabrizi (Institute of Neurology, UCL) and Peter Holmans, in Cardiff to integrate genetic and gene expression data from HD subjects to explore underlying pathology important in disease (10.1093/hmg/ddw142). In collaboration with Sarah Tabrizi, Henry Houlden, Alexandra Durr and other collaborators we also showed that the signal we saw modifying onset in HD modifies onset in a series of spinocerebellar ataxias also caused by repeat expansion mutations (10.1002/ana.24656). This implicates the expansion in the DNA as the main source of modification of the age of onset in these diseases, rather than more downstream events. We went on to demonstrate that variation in MSH3 on chromosome 5 is associated with how fast HD progresses (.https://doi.org/10.1016/S1474-4422(17)30161-8). We are now exploring how these genes affect HD using cellular and animal models of disease with funding from CHDI, the Dementia Discovery Fund, the Wellcome Trust and the MRC.
Alzheimer’s disease (AD)
I led the work that implicated cholesterol metabolism and innate immune involvement in disease aetiology using pathway analysis (10.1038/mp.2015.23) and the follow up analysis in the International Genomics of Alzheimer's disease Project (IGAP) (https://doi.org/10.1016/j.jalz.2014.05.1757). I have been collborating with Phil Taylor and Paul Morgan in the Systems Immunity University Research Institute to examine the mechanism underlying the immune signal in AD.
HD lab group members
Tom Massey: clinical neurologist, WCAT, MRC and Philip Berthold research fellow
Lyn Elliston: research technician
Sergey Lobanov: postdoctoral research associate, bioniformatics
Jasmine Donaldson: research associate
Kyle Fears: research associate
Bran McAllister: research associate
Freja Sadler: graduate student
Ant Warland: graduate student
Joe Stone: research assistant
Caroline Binda: research assistant
Gareth Edwards: research associate
Matthew Bareford: research technician
We welcome applications from prospective graduate students. Funded studentship opportunities can be found on the University website and FindaPhD.com. We welcome a range of visiting researchers including Erasmus students.
We are currently supported by generous funding from:
CHDI https://chdifoundation.org/
MRC
LoQus23 Therapeutics
UK Dementia Research Institute
Supervision
I am interested in supervising PhD students in the following areas:
- Huntington's disease
- neurodegeneration
- genetic modifiers
- short tandem repeats
- stem cell and mouse models of disease
Current supervision
Past projects
Recent successful PhD students:
- Main supervisor Jasmine Donaldson, “Characterising the DNA damage response in cellular models of Huntington’s disease”, awarded 2019
- Main supervisor Branduff McAllister, “Identification and characterisation of genetic variation that modifies age at onset in Huntington’s disease” awarded 2019
- Co-supervisor Ruth Jones "Targeting Microglia in Alzheimer's Disease", awarded 2019
- Co-supervisor Anna Barrett “Creating Cellular Models for the Functional Characterisation of Alzheimer's Disease Risk Variants”, awarded 2018;
- Main supervisor, Jordan Scoberg-Evans, “Examining the biological basis of deteriorating cognition in Huntington’s disease” awarded 2016;
- Main supervisor, Kathryn Bowles, “The role of huntingtin phosphorylation in Huntington’s disease” awarded 2013;